Bio News
Novo Nordisk’s ziltivekimab failed to reduce major cardiovascular events in a phase 3 trial, recording a hazard ratio (HR) of 0.99. The study compared ziltivekimab with placebo in more than 6,300 patients with atherosclerotic cardiovascular disease, chronic kidney disease (CKD) and inflammation. Results from the Hermes trial in patients with heart failure and the Artemis trial in patients after acute myocardial infarction are expected in the first half of next year, but analysts believe the likelihood of success is low.
BIOBOOK TEAM
biobookmedia@biobook.co.krRoche’s New Drug for Uveitic Macular Edema Faces FDA Decision in July 2027
BMS Reports Concurrent Phase 3 Success in Idiopathic Pulmonary Fibrosis and Solid Tumors
Merck’s $1.3 trillion eye disease drug raises safety and efficacy concerns: “Limited competitiveness”
CHA Biotech Holds 24.23% Stake in CMG Pharmaceutical as Share Consolidation Reduces Its Share Count
Rural Development Administration Develops Two Molecular Markers to Identify Leaf Splitting in Squash
MFDS Begins Distribution of Internationally Certified Reference Materials, Including 24 New Items, for a Total of 882
